PHLAX: PGIM Jennison Health Sciences A

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

PHLAX PGIM Jennison Health Sciences A

  • Fund
  • PHLAX
  • Price as of: Dec 06, 2019
  • $43.17
    + $0.40 + 0.94%

Profile

PHLAX - Profile

Vitals

  • YTD Return 13.1%
  • 3 Yr Annualized Return 4.9%
  • 5 Yr Annualized Return -4.4%
  • Net Assets $1.91 B
  • Holdings in Top 10 38.3%

52 WEEK LOW AND HIGH

$43.17
$35.23
$47.57

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.14%

SALES FEES

  • Front Load 5.50%
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 36.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

Closed to new investors as of Jun 29, 2012
  • Standard (Taxable) $2,500
  • IRA $1,000

Fund Classification


Distributions

  • YTD Total Return 13.1%
  • 3 Yr Annualized Total Return 4.9%
  • 5 Yr Annualized Total Return -4.4%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.64%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Semi-Annually

Fund Details

  • Legal Name
    PGIM Jennison Health Sciences Fund
  • Fund Family Name
    PGIM Funds (Prudential)
  • Inception Date
    Jun 30, 1999
  • Shares Outstanding
    N/A
  • Share Class
    A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    David Chan

Fund Description

The Prudential Jennison Health Sciences Fund Class A (PHLAX) is an actively managed fund that focuses on the health care sector of the world’s equity markets. PHLAX can own drug, health care, medicine, medical devices, and biotechnology stocks and can invest in any market-cap size. The fund uses various fundamental analyses to uncover the best growth stocks within the health care sector.

Even with its low costs, PHLAX’s focus on riskier segments of the equity markets makes the fund a satellite position only within a broader equity portfolio. The fund is managed by Jennison Associates LLC.


Get Updates About PHLAX

Sign up for Advisor Access to receive email updates about PHLAX competitors, news, CE accredited webcasts and more.

Please Enter Your Email
Please Select Your Advisor Type

Categories

Performance

PHLAX - Performance

Return Ranking - Trailing

Period PHLAX Return Category Return Low Category Return High Rank in Category (%)
YTD 13.1% 9.8% 45.5% 87.18%
1 Yr -7.5% -15.7% 25.1% 95.73%
3 Yr 4.9%* -12.0% 24.7% 84.40%
5 Yr -4.4%* -11.1% 14.8% 83.65%
10 Yr 8.6%* -1.8% 16.8% 66.29%

* Annualized

Return Ranking - Calendar

Period PHLAX Return Category Return Low Category Return High Rank in Category (%)
2018 -14.8% -25.3% 21.5% 83.78%
2017 24.9% -10.8% 43.9% 16.51%
2016 -17.7% -31.6% 6.9% 63.21%
2015 -8.5% -20.4% 13.8% 82.52%
2014 18.0% -5.8% 31.5% 44.79%

Total Return Ranking - Trailing

Period PHLAX Return Category Return Low Category Return High Rank in Category (%)
YTD 13.1% 9.8% 45.5% 87.18%
1 Yr -7.5% -15.7% 33.7% 95.73%
3 Yr 4.9%* -12.0% 26.3% 87.16%
5 Yr -4.4%* -11.1% 16.8% 89.42%
10 Yr 8.6%* -1.8% 18.0% 79.78%

* Annualized

Total Return Ranking - Calendar

Period PHLAX Return Category Return Low Category Return High Rank in Category (%)
2018 -14.8% -25.3% 22.2% 84.68%
2017 24.9% -10.8% 45.8% 18.35%
2016 -17.7% -26.4% 8.7% 76.42%
2015 -8.5% -16.6% 15.2% 85.44%
2014 18.0% -5.8% 36.7% 67.71%

NAV & Total Return History


Holdings

PHLAX - Holdings

Concentration Analysis

PHLAX Category Low Category High PHLAX % Rank
Net Assets 1.91 B 3.25 M 47.5 B 27.56%
Number of Holdings 76 26 388 54.33%
Net Assets in Top 10 687 M 913 K 17.4 B 28.35%
Weighting of Top 10 38.26% 21.3% 77.1% 69.29%

Top 10 Holdings

  1. Illumina Inc 5.32%
  2. Biomarin Pharmaceutical Inc 4.50%
  3. Sage Therapeutics Inc 4.23%
  4. Intuitive Surgical Inc 4.14%
  5. Sarepta Therapeutics Inc 3.70%
  6. UnitedHealth Group Inc 3.48%
  7. Vertex Pharmaceuticals Inc 3.38%
  8. AstraZeneca PLC ADR 3.31%
  9. Boston Scientific Corp 3.27%
  10. Natera Inc 2.93%

Asset Allocation

Weighting Return Low Return High PHLAX % Rank
Stocks
99.28% 90.21% 103.54% 34.65%
Cash
0.61% 0.00% 9.79% 66.14%
Other
0.11% -27.41% 5.17% 36.22%
Preferred Stocks
0.00% 0.00% 1.08% 45.67%
Convertible Bonds
0.00% 0.00% 1.54% 42.52%
Bonds
0.00% 0.00% 20.60% 42.52%

Stock Sector Breakdown

Weighting Return Low Return High PHLAX % Rank
Healthcare
98.21% 56.22% 99.75% 25.98%
Basic Materials
0.72% 0.00% 1.94% 3.94%
Financial Services
0.34% 0.00% 5.93% 11.81%
Utilities
0.00% 0.00% 0.00% 34.65%
Technology
0.00% 0.00% 16.35% 61.42%
Real Estate
0.00% 0.00% 5.81% 40.16%
Industrials
0.00% 0.00% 2.40% 43.31%
Energy
0.00% 0.00% 0.43% 37.80%
Communication Services
0.00% 0.00% 1.02% 38.58%
Consumer Defense
0.00% 0.00% 34.83% 40.16%
Consumer Cyclical
0.00% 0.00% 10.49% 40.16%

Stock Geographic Breakdown

Weighting Return Low Return High PHLAX % Rank
US
88.71% 58.61% 99.93% 25.98%
Non US
10.57% 0.00% 40.52% 70.08%

Expenses

PHLAX - Expenses

Operational Fees

PHLAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.14% 0.10% 4.94% 55.56%
Management Fee 0.72% 0.09% 1.30% 55.91%
12b-1 Fee 0.30% 0.00% 1.00% 51.39%
Administrative Fee N/A 0.01% 0.40% N/A

Sales Fees

PHLAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load 5.50% 2.50% 5.75% 57.69%
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

PHLAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 0.75% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PHLAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 36.00% 0.00% 341.00% 38.98%

Distributions

PHLAX - Distributions

Dividend Yield Analysis

PHLAX Category Low Category High PHLAX % Rank
Dividend Yield 0.00% 0.00% 3.95% 43.31%

Dividend Distribution Analysis

PHLAX Category Low Category High Category Mod
Dividend Distribution Frequency Semi-Annually Annually Monthly Annually

Net Income Ratio Analysis

PHLAX Category Low Category High PHLAX % Rank
Net Income Ratio -0.64% -2.24% 2.12% 75.21%

Capital Gain Distribution Analysis

PHLAX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History

View More +

Fund Manager Analysis

PHLAX - Fund Manager Analysis

Managers

David Chan


Start Date

Tenure

Tenure Rank

Jun 30, 1999

20.43

20.4%

David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.

Debra Netschert


Start Date

Tenure

Tenure Rank

Jan 28, 2015

4.84

4.8%

Debra Netschert is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Ms. Netschert joined Jennison Associates in January 2008. Prior to Jennison, Ms. Netschert worked at Magnetar Capital where she was a senior analyst responsible for health care coverage with an emphasis on biotechnology and pharmaceutical industries. Prior to her experience at Magnetar Capital, Ms. Netschert worked at Amaranth Advisors as a biotechnology analyst. From 2002 to 2004, she was vice president and senior analyst for biotechnology at Lazard Capital Markets. Ms. Netschert began her research career as an associate biotechnology analyst at UBS in 2000. She received her BS and MS from Boston University.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.34 22.22 9.78 19.59